The potential of biologics for the treatment of asthma (original) (raw)

• Holgate, S. T. et al. A new look at the pathogenesis of asthma. Clin. Sci. 118, 439–450 (2010).
  CAS Google Scholar
• Anderson, G. P. Endotyping asthma: new insights into key pathogenetic mechanisms in a complex, heterogeneous disease. Lancet 372, 1107–1119 (2008).
  PubMed Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. GINA [online], (2005).
• Bateman, E. D. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL (GOAL) study. Am. J. Respir. Crit. Care Med. 170, 836–844 (2004).
  PubMed Google Scholar
• Fanta, C. H. Drug therapy: asthma. N. Engl. J. Med. 360, 1002–1014 (2009).
  CAS PubMed Google Scholar
• Boulet, L. P. Influence of comorbid conditions on asthma. Eur. Respir. J. 33, 897–906 (2009).
  PubMed Google Scholar
• Serra-Batlles, J., Plaza, V., Morejon, E., Comella, A. & Brugues, J. Costs of asthma according to the degree of severity. Eur. Respir. J. 12, 1322–1326 (1998).
  CAS PubMed Google Scholar
• Heaney, L. G. et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 58, 561–566 (2003).
  CAS PubMed PubMed Central Google Scholar
• Dolan, C. M. et al. Design of baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann. Allergy Asthma Immunol. 92, 32–39 (2004).
  PubMed Google Scholar
• Haselkorn, T., Borish, L., Miller, D. P., Weiss, S. T. & Wong, D. A. High prevalence of skin test positivity in severe or difficult-to-treat asthma. J. Asthma 43, 745–752 (2006).
  CAS PubMed Google Scholar
• Gould, H. J. & Sutton, B. J. IgE in allergy and asthma today. Nature Rev. Immunol. 8, 205–217 (2008).
  CAS Google Scholar
• Barnes, P. J. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Invest. 118, 3546–3556 (2008).
  CAS PubMed PubMed Central Google Scholar
• Al-Ramly, W. et al. TH17-associated cytokines (IL-17A and IL-17F) in severe asthma. J. Allergy Clin. Immunol. 123, 1185–1187 (2009).
  Google Scholar
• Walsh, G. M. Novel cytokine-directed therapies for asthma. Discov. Med. 11, 283–291 (2011).
  PubMed Google Scholar
• Gruenberg, D. & Busse, W. Biologic therapies for asthma. Curr. Opin. Pulm. Med. 16, 19–24 (2010).
  PubMed Google Scholar
• Rodrigo, G. J., Neffen, H. & Castro-Rodriguez, J. A. Efficacy and safety of subcutaneous omalizumab versus placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139, 28–35 (2011).
  CAS PubMed Google Scholar
• Hansbro, P. M., Kaiko, G. E. & Foster, P. S. Cytokine/anti-cytokine therapy — novel treatments for asthma? Br. J. Pharmacol. 163, 81–95 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bouzigon, E. et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. N. Engl. J. Med. 359, 1985–1994 (2008).
  CAS PubMed Google Scholar
• Wenzel, S. E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Med. 18, 716–725 (2012).
  CAS PubMed Google Scholar
• Moore, W. C. et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J. Allergy Clin. Immunol. 119, 405–413 (2007).
  PubMed PubMed Central Google Scholar
• Phelan, P. D., Robertson, C. F. & Olinsky, A. The Melbourne Asthma Study: 1964–1999. J. Allergy Clin. Immunol. 109, 89–94 (2002).
  Google Scholar
• Wenzel, S. Severe asthma: from characteristics to phenotypes to endotypes. Clin. Exp. Allergy 42, 650–658 (2012).
  CAS PubMed Google Scholar
• Barrett, N. A. & Austen, K. F. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 31, 425–437 (2009).
  CAS PubMed PubMed Central Google Scholar
• Woodruff, P. G. et al. Th2-driven inflammation defines major sub-phenotypes of asthma. Am. J. Respir. Crit. Care Med. 180, 388–395 (2009). This study is a cornerstone in the efforts aimed at characterizing the various asthma phenotypes and the different underlying mechanisms.
  CAS PubMed PubMed Central Google Scholar
• Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088–1098 (2011). This important study suggests that it is possible to use the IL-13-specific monoclonal antibody lebrikizumab for the treatment of patients with specific asthma phenotypes, who are selected on the basis of the expression of appropriate biomarkers such as periostin.
  CAS PubMed Google Scholar
• Sokol, C. L., Barton, G. M., Farr, A. G. & Medzhitov, R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nature Immunol. 9, 310–318 (2008).
  CAS Google Scholar
• Ying, S. et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J. Immunol. 174, 8183–8190 (2005).
  CAS PubMed Google Scholar
• Nguyen, K. D., Vanichsarn, C. & Nadeau, K.C. TSLP directly impairs pulmonary Treg function: association with aberrant tolerogenic immunity in asthmatic airway. Allergy Asthma Clin. Immunol. 6, 4 (2010).
  CAS PubMed PubMed Central Google Scholar
• Hamid, Q. & Tulic, M. Immunobiology of asthma. Annu. Rev. Physiol. 71, 489–507 (2009).
  CAS PubMed Google Scholar
• Collins, P. D., Marleau, S., Griffiths-Johnson, D. A., Jose, P. J. & Williams, T. J. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J. Exp. Med. 182, 1169–1174 (1995).
  CAS PubMed Google Scholar
• Zietkowski, Z., Tomasiak, M. M., Skiepko, R. & Bodzenta-Lukaszyk, A. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respir. Med. 102, 1198–2202 (2008).
  CAS PubMed Google Scholar
• Finkelman, F. et al. IL-4 is required to generate and sustain in vivo IgE responses. J. Immunol. 141, 2335–2341 (1988).
  CAS PubMed Google Scholar
• Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261–2263 (1998).
  CAS PubMed PubMed Central Google Scholar
• Veldohen, M. et al. Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nature Immunol. 9, 1341–1346 (2008).
  Google Scholar
• Chang, H. C. et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nature Immunol. 11, 527–534 (2010).
  CAS Google Scholar
• The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur. Respir. J. 22, 470–477 (2003).
• Zhao, Y., Yang, J., Gao, Y. D. & Guo, W. Th17 immunity in patients with allergic asthma. Int. Arch. Allergy Immunol. 151, 297–307 (2010).
  CAS PubMed Google Scholar
• Lukacs, N. W., Strieter, R. M., Chensue, S. W., Widmer, M. & Kunkel, S. L. TNF-α mediates recruitment of neutrophils and eosinophils during airway inflammation. J. Immunol. 154, 5411–5417 (1995).
  CAS PubMed Google Scholar
• Amrani, Y., Panettieri, R. A. Jr., Frossard, N. & Bronner, C. Activation of the TNF-α-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 15, 55–63 (1996).
  CAS PubMed Google Scholar
• ten Brinke, A. et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur. Respir. J. 26, 812–818 (2005).
  CAS PubMed Google Scholar
• Contoli, M. & et al. Role of deficient type III interferon-λ production in asthma exacerbations. Nature Med. 12, 1023–1026 (2006).
  CAS PubMed Google Scholar
• Matsumoto, K. et al. Frequency of Foxp3+CD4+CD25+ T cells is associated with the phenotypes of allergic asthma. Respirology 14, 187–194 (2009).
  PubMed Google Scholar
• Provoost, S. et al. Decreased FOXP3 protein expression in patients with asthma. Allergy 64, 1539–1546 (2009).
  CAS PubMed Google Scholar
• Abdulamir, A. S. et al. Severity of asthma: the role of CD25+, CD30+, NF-κB, and apoptotic markers. J. Investig. Allergol. Clin. Immunol. 19, 218–224 (2009).
  CAS PubMed Google Scholar
• Turato, G. et al. Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma. Am. J. Respir. Crit. Care Med. 178, 476–482 (2008).
  PubMed Google Scholar
• Jeffery, P. K. Remodeling in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164, S28–S38 (2001).
  CAS PubMed Google Scholar
• Tliba, O. & Panettieri, R. A. Jr. Noncontractile functions of airway smooth muscle in asthma. Annu. Rev. Physiol. 71, 509–535 (2009).
  CAS PubMed Google Scholar
• Payne, D. N. et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am. J. Respir. Crit. Care Med. 167, 78–82 (2003).
  PubMed Google Scholar
• Saglani, S. et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am. J. Respir. Crit. Care Med. 176, 858–864 (2007).
  PubMed Google Scholar
• Ebina, M., Takahashi, T., Chiba, T. & Motomiya, M. Cellular hypertrophy and hyperplasia of airway smooth muscle underlying bronchial asthma. A 3D morphometric study. Am. Rev. Respir. Dis. 148, 720–726 (1993).
  CAS PubMed Google Scholar
• Bai, T. R., Cooper, J., Koelmeyer, T., Pare, P. D. & Weir, T. D. The effect of age and duration of disease on airway structure in fatal asthma. Am. J. Respir. Crit. Care Med. 162, 663–669 (2000).
  CAS PubMed Google Scholar
• Salvato, G. Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 56, 902–906 (2001).
  CAS PubMed PubMed Central Google Scholar
• Hoshino, M., Takahashi, M. & Aoike, N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. 107, 295–301 (2001).
  CAS PubMed Google Scholar
• Hastie, A. T. et al. Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung fibroblasts after segmental allergen challenge. Am. J. Respir. Crit. Care Med. 165, 266–272 (2002).
  PubMed Google Scholar
• Hackett, T. L. et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-β1. Am. J. Respir. Crit. Care Med. 180, 122–133 (2009).
  CAS PubMed Google Scholar
• Heijink, I. H., Postma, D. S., Noordhoek, J. A., Broekma, M. & Kapus, A. House dust mite-promoted epithelial-to-mesenchymal transition in human bronchial epithelium. Am. J. Respir. Cell. Mol. Biol. 42, 69–79 (2010).
  CAS PubMed Google Scholar
• Vignola, A. M. et al. Transforming growth factor-β expression in mucosal biopsies in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 156, 591–599 (1997).
  CAS PubMed Google Scholar
• Doherty, T. & Broide, D. Cytokines and growth factors in airway remodeling in asthma. Curr. Opin. Immunol. 19, 676–680 (2007).
  CAS PubMed Google Scholar
• Pascual, R. M. & Peters, S. P. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J. Allergy Clin. Immunol. 116, 477–486 (2005).
  PubMed Google Scholar
• Ishizaka, K. & Ishizaka, T. Identification of γE antibodies as a carrier of reaginic activity. J. Immunol. 99, 1187–1198 (1967).
  CAS PubMed Google Scholar
• Pelaia, G., Renda, T., Romeo, P., Busceti, M. T. & Maselli, R. Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther. Adv. Respir. Res. 2, 409–421 (2008).
  Google Scholar
• Presta, L. G. et al. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623–2632 (1993).
  CAS PubMed Google Scholar
• Rivera, J. & Gilfillan, A. M. Molecular regulation of mast cell activation. J. Allergy Clin. Immunol. 117, 1214–1225 (2006).
  CAS PubMed Google Scholar
• Galli, S. J. & Tsai, M. IgE and mast cells in allergic disease. Nature Med. 18, 693–704 (2012).
  CAS PubMed Google Scholar
• Shields, R. L. et al. Inhibition of allergic reactions with antibodies to IgE. Int. Arch. Allergy Immunol. 107, 308–312 (1995).
  CAS PubMed Google Scholar
• Holgate, S. et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 115, 459–465 (2005).
  CAS PubMed Google Scholar
• Novak, N. et al. Evidence for a differential expression of the FcɛRIγ chain in dendritic cells of atopic and non atopic donors. J. Clin. Invest. 111, 1047–1056 (2003).
  CAS PubMed PubMed Central Google Scholar
• Campbell, A. M. et al. Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics. Am. J. Respir. Cell. Mol. Biol. 19, 92–97 (1998).
  CAS PubMed Google Scholar
• Gounni, A. S. et al. Human airway smooth muscle cells express the high affinity receptor for IgE (FcɛRI): a critical role of FcɛRI in human airway smooth muscle function. J. Immunol. 175, 2613–2621 (2005).
  CAS PubMed Google Scholar
• Huang, Y. C., Leyko, B. & Frier, M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann. Allergy Asthma Immunol. 95, 443–451 (2005).
  CAS PubMed Google Scholar
• Zietkowski, Z., Skiepko, R., Tomasiak-Lozowska, M. M. & Bodzenta-Lukaszyk, A. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma. Respiration 80, 534–542 (2010).
  CAS PubMed Google Scholar
• Hoshino, M. & Ohtawa, J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 83, 520–528 (2012).
  CAS PubMed Google Scholar
• Riccio, A. M. et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int. J. Immunopathol. Pharmacol. 25, 475–484 (2012). This very interesting study, carried out in patients with severe persistent allergic asthma, shows that the use of omalizumab as an add-on treatment for 1 year can modulate airway remodelling by reducing the thickness of the airway RBM.
  CAS PubMed Google Scholar
• Stirling, R. G., van Rensen, E. I., Barnes, P. J. & Chung, K. F. Interleukin-5 induces CD34+ eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am. J. Respir. Crit. Care Med. 164, 1403–1409 (2001).
  CAS PubMed Google Scholar
• Garlisi, C. G. et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am. J. Respir. Cell. Mol. Biol. 20, 248–255 (1999).
  CAS PubMed Google Scholar
• Mauser, P. et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am. J. Respir. Crit. Care Med. 152, 467–472 (1995).
  CAS PubMed Google Scholar
• Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M. & Geba, G. P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy 42, 712–737 (2012).
  CAS PubMed Google Scholar
• Leckie, M. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356, 2144–2148 (2000).
  CAS PubMed Google Scholar
• Food-Page, P. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176, 1062–1071 (2007).
  Google Scholar
• Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973–984 (2009).
  CAS PubMed PubMed Central Google Scholar
• Nair, P. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360, 985–993 (2009). These two studies demonstrated for the first time that the IL-5-targeted monoclonal antibody mepolizumab can decrease the frequency of asthma exacerbations and corticosteroid use in small selected groups of patients with severe eosinophilic steroid-dependent asthma, who were recruited to the study on the basis of having high eosinophil levels in induced sputum.
  CAS PubMed Google Scholar
• Pavord, I. D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651–659 (2012). This large clinical study showed that mepolizumab decreased the frequency of asthma exacerbations, even at low doses, in a large number of patients with severe asthma who had sputum and blood eosinophilia as well as elevated levels of easily measurable exhaled nitric oxide.
  CAS PubMed Google Scholar
• Castro, M. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184, 1125–1132 (2011).
  CAS PubMed Google Scholar
• Busse, W. W. et al. Safety profile, pharmacokinetics and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 125, 1237–1244 (2010).
  CAS PubMed Google Scholar
• Ghazi, A., Trikha, A. & Calhoun, W. J. Benralizumab — a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity — a novel approach for the treatment of asthma. Expert Opin. Biol. Ther. 12, 113–118 (2012).
  CAS PubMed Google Scholar
• Zhou, C. Y., Crocker, I. C., Koenig, G., Romero, F. A. & Townley, R. G. Anti-interleukin-4 inhibits immunoglobulin E production in a murine model of atopic asthma. J. Asthma 34, 195–201 (1997).
  CAS PubMed Google Scholar
• Corry, D. B. et al. Interleukin-4, but not interleukin-5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J. Exp. Med. 183, 109–117 (1996).
  CAS PubMed Google Scholar
• Hart, T. K. et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 130, 93–100 (2002).
  CAS PubMed PubMed Central Google Scholar
• Shames, R. S. et al. The safety and pharmacokinetics of SB240683 (anti-interleukin-4 humanized monoclonal antibody) in patients with mild to moderate asthma. J. Allergy Clin. Immunol. 163, A523 (2001).
  Google Scholar
• Henderson, W. R. Jr., Chi, E. Y. & Maliszewski, W. J. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J. Immunol. 164, 1086–1095 (2000).
  CAS PubMed Google Scholar
• Borish, L. C. et al. IL-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816–1823 (1999).
  CAS PubMed Google Scholar
• Borish, L. C. et al. IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963–970 (2001).
  CAS PubMed Google Scholar
• Steinke, J. W. Anti-interleukin-4 therapy. Immunol. Allergy Clin. North Am. 24, 599–614 (2004).
  PubMed Google Scholar
• Blanchet, M. R., Gold, M. J. & McNagny, K. M. Mouse models to evaluate the function of genes associated with allergic airway disease. Curr. Opin. Allergy Clin. Immunol. 12, 467–474 (2012).
  CAS PubMed Google Scholar
• Reddy, A. T., Lakshmi, S. P. & Reddy, R. C. Murine model of allergen induced asthma. J. Vis. Exp. 63, e3771 (2012).
  Google Scholar
• Tomkinson, A. et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J. Immunol. 166, 5792–5800 (2001).
  CAS PubMed Google Scholar
• Tomkinson, A. et al. Inhaled versus subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy 65, 69–77 (2010).
  CAS PubMed Google Scholar
• Burmeister Getz, E., Fisher, D. M. & Fuller, R. Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J. Clin. Pharmacol. 49, 1025–1036 (2009).
  PubMed Google Scholar
• Wenzel, S. et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422–1431 (2007).
  CAS PubMed Google Scholar
• Wenzel, S. E. et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36, P3980 (2010).
  Google Scholar
• Slager, R. E. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J. Allergy Clin. Immunol. 130, 516–522 (2012). This is the first large pharmacogenetic analysis showing that a therapeutic asthma strategy based on IL-4 and IL-13 antagonism can be effective in lowering the frequency of asthma exacerbations in selected patients who have specific polymorphisms in the gene encoding the α-chain of the IL-4 receptor.
  CAS PubMed PubMed Central Google Scholar
• Perkins, C., Wills-Karp, M. & Finkelman, F. D. IL-4 induces IL-13-independent allergic airway inflammation. J. Allergy Clin. Immunol. 118, 410–419 (2006).
  CAS PubMed Google Scholar
• Maes, T., Joos, G. F. & Brusselle, G. G. Targeting interleukin-4 in asthma: lost in translation? Am. J. Respir. Cell. Mol. Biol. 47, 261–270 (2012).
  CAS PubMed Google Scholar
• Kakkar, T. et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL-4 receptor. Pharm. Res. 28, 2530–2542 (2011).
  CAS PubMed Google Scholar
• Corren, J. et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist. Am. J. Respir. Crit. Care Med. 181, 788–796 (2010).
  CAS PubMed Google Scholar
• McCusker, C. T. et al. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT6 peptide. J. Immunol. 179, 2556–2564 (2007).
  CAS PubMed Google Scholar
• Chiba, Y., Todoroki, M., Nishida, Y., Tanabe, M. & Misawa, M. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am. J. Respir. Cell. Mol. Biol. 41, 516–524 (2009).
  CAS PubMed Google Scholar
• Wills-Karp, M. Interleukin-13 in asthma pathogenesis. Immunol. Rev. 202, 175–190 (2004).
  CAS PubMed Google Scholar
• Yang, G. et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 28, 224–232 (2004).
  CAS PubMed Google Scholar
• Blanchard, C. et al. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human interleukin-13 antibody (CAT-354). Clin. Exp. Allergy 35, 1096–1103 (2005).
  CAS PubMed Google Scholar
• Singh, D. et al. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm. Med. 10, 3 (2010).
  PubMed PubMed Central Google Scholar
• Gauvreau, G. M. et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med. 183, 1007–1014 (2011).
  CAS PubMed Google Scholar
• Cheng, G. et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am. J. Respir. Crit. Care Med. 166, 409–416 (2002).
  PubMed Google Scholar
• White, B., Leon, F., White, W. & Robbie, G. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy volunteers. Clin. Ther. 31, 728–740 (2009).
  CAS PubMed Google Scholar
• Parker, J. M. et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm. Med. 11, 14 (2011).
  CAS PubMed PubMed Central Google Scholar
• Yamashita, N. et al. Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony stimulating factor (GM-CSF). Cell. Immunol. 219, 92–97 (2002).
  CAS PubMed Google Scholar
• Krinner, E. M. et al. A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol. Immunol. 44, 916–925 (2007).
  CAS PubMed Google Scholar
• Lukacs, N. W. et al. TNF-α mediates recruitment of neutrophils and eosinophils during airway inflammation. J. Immunol. 154, S411–S417 (1995).
  Google Scholar
• Howarth, P. H. et al. Tumour necrosis factor-α (TNF-α) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60, 1012–1018 (2005).
  CAS PubMed PubMed Central Google Scholar
• Berry, M. A. et al. Evidence of a role of tumor necrosis factor-α in refractory asthma. N. Engl. J. Med. 354, 697–708 (2006).
  CAS PubMed Google Scholar
• Holgate, S. T. et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur. Respir. J. 37, 1352–1359 (2011).
  CAS PubMed Google Scholar
• Erin, E. M. et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am. J. Respir. Crit. Care Med. 174, 753–762 (2006).
  CAS PubMed Google Scholar
• Wenzel, S. E. et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med. 179, 549–558 (2009). This paper reports the results of a large clinical trial in patients with severe persistent asthma, which showed that the TNFα-targeted monoclonal antibody golimumab has an unfavourable risk-benefit profile, suggesting that such a therapeutic strategy may not be suitable for all patients with severe asthma.
  CAS PubMed Google Scholar
• Hellings, P. W. et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am. J. Respir. Cell. Mol. Biol. 28, 42–50 (2003).
  CAS PubMed Google Scholar
• Wakashing, H. et al. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am. J. Respir. Crit. Care Med. 178, 1023–1032 (2008).
  Google Scholar
• Li, Y. et al. Silencing IL-23 expression by a small hairpin RNA protects against asthma in mice. Exp. Mol. Med. 43, 197–204 (2011).
  PubMed PubMed Central Google Scholar
• Park, S. J. & Lee, Y. C. Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir. Res. 11, 78 (2010).
  PubMed PubMed Central Google Scholar
• Tamachi, T. et al. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J. Allergy Clin. Immunol. 118, 606–614 (2006).
  CAS PubMed Google Scholar
• Kearley, J., Buckland, K. F., Mathie, S. A. & Lloyd, C. M. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am. J. Respir. Crit. Care Med. 179, 772–781 (2009).
  CAS PubMed PubMed Central Google Scholar
• Fujita, J. et al. Interleukin-33 induces interleukin-17F in bronchial epithelial cells. Allergy 67, 744–750 (2012). This very interesting study, in human bronchial epithelial cells, showed that mouse antibodies directed against the ST2 receptor of the innate cytokine IL-33 are able to inhibit IL-33-induced expression of IL-17F. Therefore, these findings suggest that the IL-33–IL-17F axis is involved in allergic airway inflammation and can be considered as a novel therapeutic target.
  CAS PubMed Google Scholar
• Shi, L. et al. Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells. Clin. Immunol. 129, 202–210 (2008).
  CAS PubMed Google Scholar
• Li, J. J. et al. IL-27/IFN-γ induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages. J. Immunol. 185, 4401–4409 (2010).
  CAS PubMed Google Scholar
• Masuda, E. S. & Schmitz, J. Syk inhibitors as treatment for allergic rhinitis. Pulm. Pharmacol. Ther. 21, 461–467 (2008).
  CAS PubMed Google Scholar
• Stenton, G. R. et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J. Immunol. 169, 1028–1036 (2002).
  CAS PubMed Google Scholar
• Meltzer, E. O., Berkowitz, R. B. & Grossbard, E. B. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J. Allergy Clin. Immunol. 115, 791–796 (2005).
  CAS PubMed Google Scholar
• Szefler, S. J. et al. Asthma outcomes: biomarkers. J. Allergy Clin. Immunol. 129, S9–S23 (2012).
  PubMed PubMed Central Google Scholar
• Massanari, M. et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir. Med. 104, 188–196 (2010).
  CAS PubMed Google Scholar
• Terracciano, R. et al. Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases. Proteomics 11, 3402–3414 (2011).
  CAS PubMed Google Scholar
• von Mutius, E. & Drazen, J. M. Choosing asthma step-up care. N. Engl. J. Med. 362, 1042–1043 (2010).
  CAS PubMed Google Scholar
• Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184–190 (2001).
  CAS PubMed Google Scholar
• Solér, M. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254–261 (2001).
  PubMed Google Scholar
• Holgate, S. T. et al. Efficacy and tolerability of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 34, 632–638 (2004).
  CAS PubMed Google Scholar
• Vignola, A. M. et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59, 709–717 (2004).
  CAS PubMed Google Scholar
• Ayres, J. G. et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59, 701–708 (2004).
  CAS PubMed Google Scholar
• Humbert, M. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60, 309–316 (2005). This is one of the most important pre-marketing trials showing that an add-on treatment with omalizumab improves the control of inadequately controlled allergic asthma, thus reducing the occurrence of disease exacerbations, emergency hospital visits and hospitalizations.
  CAS PubMed Google Scholar
• Pelaia, G. et al. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma. Int. J. Clin. Pharmacol. Ther. 49, 713–721 (2011).
  CAS PubMed Google Scholar
• Molimard, M. de Blay, F., Didier, A. & Le Gros, V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir. Med. 102, 71–76 (2008).
  PubMed Google Scholar
• Cazzola, M. et al. Italian real-life experience of omalizumab. Respir. Med. 104, 1410–1416 (2010). This is a post-marketing study that, in addition to corroborating the findings of pre-marketing clinical trials, highlights the ability of omalizumab to reduce the use of other asthma drugs such as corticosteroids, leukotriene inhibitors and theophylline.
  CAS PubMed Google Scholar
• Miller, C. W. T., Krishnaswamy, N., Johnston, C. & Krishnaswamy, G. Severe asthma and the omalizumab option. Clin. Mol. Allergy 6, 4 (2008).
  PubMed PubMed Central Google Scholar
• Busse, W. et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J. Allergy Clin. Immunol. 129, 983–989 (2012).
  CAS PubMed Google Scholar
• Cox, L. et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol. 120, 1373–1377 (2007).
  CAS PubMed Google Scholar
• US Food and Drug Adminisration (FDA). Early communication about an ongoing safety review of omalizumab (marketed as Xolair). FDA website [online], (2009).